Zymeworks Inc., a clinical-stage biotechnology company, has announced the appointment of Greg Ciongoli and Robert E. Landry to its Board of Directors, effective August 10, 2025. Both appointees will also serve as members of the audit committee. This change comes as part of Zymeworks' strategy to advance its development programs and support its long-term growth objectives. Troy Cox, a board member since 2019, has stepped down.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.